Dublin, May 30, 2017 -- Research and Markets has announced the addition of the "Non-Small Cell Lung Cancer (NSCLC) Disease Forecast and Market Analysis to 2035" report to their offering.
Lung cancer is a disease in which the cells in lung tissue grow uncontrollably. More than 80% of lung cancers are non-small cell lung cancers (NSCLC), with the exact proportion depending on the country in question. The main types of NSCLC are squamous cell carcinoma, adenocarcinoma, and large cell carcinoma.
NSCLC presents significant public health problems for nearly every country, largely due to the fact that diagnosis generally happens in the advanced stages, and there is a high death rate associated with the disease.
The future of NSCLC treatment will reflect the era of personalized therapies as mutation status becomes one of the main determinants of treatment choice.
Key Topics Covered:
1. FORECAST: NON-SMALL CELL LUNG CANCER IN THE US, JAPAN, AND 5EU
- Executive Summary
- Market Overview and Trends
- Market Definition and Methodology
- abemaciclib
- Abraxane (albumin-bound paclitaxel)
- Alecensa (alectinib)
- Alimta (pemetrexed)
- atezolizumab
- Avastin (bevacizumab)
- avelumab
- AZD9291
- brigatinib
- Cyramza (ramucirumab)
- durvalumab
- ganetespib
- Gilotrif (afatinib)
- Iressa (gefitinib)
- Keytruda (pembrolizumab)
- necitumumab
- Opdivo (nivolumab)
- rociletinib
- selumetinib
- Tarceva (erlotinib)
- TG4010
- tremelimumab
- Vargatef (nintedanib)
- veliparib
- Xalkori (crizotinib)
- Yervoy (ipilimumab)
- Zykadia (ceritinib)
2. TREATMENT: NON-SMALL CELL LUNG CANCER IN THE US, JAPAN, AND 5EU
- Executive Summary
- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Current Treatment Options
3. EPIDEMIOLOGY: NON-SMALL CELL LUNG CANCER IN THE US, JAPAN, AND 5EU
- Executive Summary
- Disease Definition
- Global Variation
- Risk Factors
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations
- Bibliography
4. MARKETED DRUGS: NON-SMALL CELL LUNG CANCER
- Executive Summary
- Product Overview
- Product profile: Alecensa
- Product profile: Alimta
- Product profile: Avastin
- Product profile: Cyramza
- Product profile: Gilotrif
- Product profile: Iressa
- Product profile: Keytruda
- Product profile: Opdivo
- Product profile: Portrazza
- Product profile: Tagrisso
- Product profile: Tarceva
- Product profile: Vargatef
- Product profile: Xalkori
- Product profile: Zykadia
5. PIPELINE: NON-SMALL CELL LUNG CANCER
- Executive Summary
- Clinical Pipeline Overview
- Clinical Trial Design
- Recently Discontinued Drugs
- Product profile (late stage): ASP8273
- Product profile (late stage): Lucanix
- Product profile (late stage): Tecentriq
- Product profile (late stage): abemaciclib
- Product profile (late stage): avelumab
- Product profile (late stage): brigatinib
- Product profile (late stage): dacomitinib
- Product profile (late stage): durvalumab
- Product profile (late stage): ensartinib
- Product profile (late stage): napabucasin
- Product profile (late stage): veliparib
For more information about this report visit http://www.researchandmarkets.com/research/2sw7tn/nonsmall_cell
CONTACT: Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Lung Cancer Drugs
